Equities research analysts expect Antares Pharma Inc (NASDAQ:ATRS) to announce earnings per share (EPS) of ($0.04) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Antares Pharma’s earnings. The lowest EPS estimate is ($0.04) and the highest is ($0.03). Antares Pharma reported earnings of ($0.03) per share during the same quarter last year, which indicates a negative year over year growth rate of 33.3%. The business is scheduled to issue its next earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Antares Pharma will report full-year earnings of ($0.10) per share for the current fiscal year, with EPS estimates ranging from ($0.13) to ($0.06). For the next year, analysts expect that the company will post earnings of $0.24 per share, with EPS estimates ranging from $0.00 to $0.60. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Antares Pharma had a negative return on equity of 17.94% and a negative net margin of 7.91%. The firm had revenue of $23.29 million during the quarter, compared to analyst estimates of $17.46 million.
ATRS has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $4.50 price objective on shares of Antares Pharma in a research note on Monday, May 6th. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. TheStreet upgraded Antares Pharma from a “d” rating to a “c” rating in a research note on Friday, March 1st. Cowen initiated coverage on Antares Pharma in a research note on Monday, February 25th. They set an “outperform” rating and a $1.99 price objective for the company. Finally, Raymond James raised their price objective on Antares Pharma from $5.25 to $5.65 and gave the company a “strong-buy” rating in a research note on Monday, March 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Antares Pharma currently has an average rating of “Buy” and a consensus price target of $4.83.
NASDAQ ATRS traded up $0.01 during mid-day trading on Thursday, reaching $2.83. 27,506 shares of the company’s stock traded hands, compared to its average volume of 916,586. Antares Pharma has a 1-year low of $2.40 and a 1-year high of $3.96. The company has a quick ratio of 1.90, a current ratio of 2.28 and a debt-to-equity ratio of 0.50. The firm has a market cap of $453.71 million, a PE ratio of -70.38 and a beta of 1.03.
In other news, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $2.67, for a total value of $80,100.00. Following the completion of the transaction, the director now owns 190,213 shares in the company, valued at approximately $507,868.71. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jacques Gonella sold 200,000 shares of Antares Pharma stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $3.65, for a total value of $730,000.00. Following the completion of the transaction, the director now owns 9,385,848 shares of the company’s stock, valued at approximately $34,258,345.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 322,078 shares of company stock valued at $1,086,334. Insiders own 5.49% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its stake in Antares Pharma by 3.1% during the 4th quarter. BlackRock Inc. now owns 10,234,202 shares of the specialty pharmaceutical company’s stock valued at $27,839,000 after acquiring an additional 304,945 shares in the last quarter. Vanguard Group Inc raised its stake in Antares Pharma by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 6,487,465 shares of the specialty pharmaceutical company’s stock valued at $21,798,000 after acquiring an additional 84,181 shares in the last quarter. Vanguard Group Inc. raised its stake in Antares Pharma by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,487,465 shares of the specialty pharmaceutical company’s stock valued at $21,798,000 after acquiring an additional 84,181 shares in the last quarter. Sargent Investment Group LLC bought a new stake in Antares Pharma during the 4th quarter valued at $8,422,000. Finally, Morgan Stanley raised its stake in Antares Pharma by 160.9% during the 1st quarter. Morgan Stanley now owns 2,130,832 shares of the specialty pharmaceutical company’s stock valued at $6,457,000 after acquiring an additional 1,314,002 shares in the last quarter. 40.48% of the stock is currently owned by hedge funds and other institutional investors.
About Antares Pharma
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Recommended Story: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.